Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.
| Website: | www.valeant.com |
| Email: | ir@valeant.com |
| Main Phone: | +1 514 744-6792 |
| Address: | 2150 Street Elzéar Boulevard West |
| State: | QC |
| City / Town: | Laval |
| Country: | CAN |
| Postal Code: | H7L 4A8 |
| Exchange: | NDD |
| CEO: | Joseph C. Papa |
| Employees: | 20700 |
| NAICS: | Pharmaceutical Preparation Manufacturing (325412) |
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
The success of companies that prioritize capital allocation, along with pressure from the investment community, has led to a greater emphasis on ROIC among executives.
There are all sorts of ways to make money on the short side.
Amazon is like a shark, and this is what it feeds on.
NovaBay Pharmaceuticals (NBY) hit positive cash flow in December 2016 as it promised, via sales of its Avenova antimicrobial eye care product. and has guided investors to 60% revenue growth in 2017.
I can no longer avert my eyes from this train wreck...
Stocks rallied last week after nearly every major Central Bank in the world expressed caution.
This partnership follows a 2015 agreement in which Valeant secured an exclusive worldwide license for its subsidiary to this product for uveitis. Valeant has maintained its right of last negotiation to license the product for other indications.
Until the next major catalyst, the bulls are in control.
You can't have opportunity without danger...
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.
| Website: | www.valeant.com |
| Email: | ir@valeant.com |
| Main Phone: | +1 514 744-6792 |
| Address: | 2150 Street Elzéar Boulevard West |
| State: | QC |
| City / Town: | Laval |
| Country: | CAN |
| Postal Code: | H7L 4A8 |
| Exchange: | NDD |
| CEO: | Joseph C. Papa |
| Employees: | 20700 |
| NAICS: | Pharmaceutical Preparation Manufacturing (325412) |
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
The success of companies that prioritize capital allocation, along with pressure from the investment community, has led to a greater emphasis on ROIC among executives.
There are all sorts of ways to make money on the short side.
Amazon is like a shark, and this is what it feeds on.
NovaBay Pharmaceuticals (NBY) hit positive cash flow in December 2016 as it promised, via sales of its Avenova antimicrobial eye care product. and has guided investors to 60% revenue growth in 2017.
I can no longer avert my eyes from this train wreck...
Stocks rallied last week after nearly every major Central Bank in the world expressed caution.
This partnership follows a 2015 agreement in which Valeant secured an exclusive worldwide license for its subsidiary to this product for uveitis. Valeant has maintained its right of last negotiation to license the product for other indications.
Until the next major catalyst, the bulls are in control.
You can't have opportunity without danger...
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume 0 | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange NDD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 27 | 63 |
| Number of Buys | 23 | 48 |
| Number of Sells | 4 | 15 |
| Net Activity | 171100 | -532589 |
| Last 10 Buys | Shares |
|---|---|
| Bruno Deschamps | 1,000 |
| Paul S. Herendeen | 1,000 |
| Joseph C. Papa | 1,000 |
| Bruno Deschamps | 1,000 |
| John A. Paulson | 1,000 |
| Bruno Deschamps | 1,000 |
| John A. Paulson | 1,000 |
| Bruno Deschamps | 1,000 |
| Bruno Deschamps | 1,000 |
| Bruno Deschamps | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| John A. Paulson | 1,000 |
| John A. Paulson | 1,000 |
| William A Ackman | 1,000 |
| J. Michael Pearson | 1,000 |
| J. Michael Pearson | 1,000 |
| J. Michael Pearson | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 35 | 35 | 35 | 35 |
| Low Target Price Estimate | 9 | 9 | 9 | 9 |
| Mean Target Price Estimate | 19.83 | 19.67 | 19.67 | 19.83 |
| Standard Deviation | 7.09 | 6.98 | 6.98 | 7.09 |
| Date of Most Recent Estimate | 06/01/18 | 05/22/18 | 05/22/18 | 06/01/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| SD | Specialized Disclosure Report | 7 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 8-K | Report of unscheduled material events or corporate changes. | 446 | 2018-06-01 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-05-10 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-08 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-08 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-08 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 5 | 5 | 5 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 3 | 4 | 4 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 3 | 3 | 3 | 4 |
| Mean Rec. | 2.38 | 2.67 | 2.67 | 2.83 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait